NVZMF vs. TRSBF, ATTBF, ABCZF, ADOIF, AIMDW, AGNPF, AKBLF, LBTSF, ALPX, and DRTSW
Should you be buying Novozymes A/S stock or one of its competitors? The main competitors of Novozymes A/S include 3SBio (TRSBF), Abattis Bioceuticals (ATTBF), Abcam (ABCZF), Adocia (ADOIF), Ainos (AIMDW), Algernon Pharmaceuticals (AGNPF), ALK-Abelló A/S (AKBLF), Almirall (LBTSF), Alopexx (ALPX), and Alpha Tau Medical (DRTSW). These companies are all part of the "biotechnology" industry.
Novozymes A/S vs.
Novozymes A/S (OTCMKTS:NVZMF) and 3SBio (OTCMKTS:TRSBF) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership.
In the previous week, 3SBio's average media sentiment score of 0.98 beat Novozymes A/S's score of 0.00 indicating that 3SBio is being referred to more favorably in the news media.
Novozymes A/S received 41 more outperform votes than 3SBio when rated by MarketBeat users.
20.4% of Novozymes A/S shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Novozymes A/S beats 3SBio on 2 of the 3 factors compared between the two stocks.
Media Sentiment Over Time
This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
NVZMF vs. The Competition
Novozymes A/S Competitors List